Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Seres Therapeutics Inc MCRB

Healthcare Biotechnology
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. The Company is engaged in developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MCRB)

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

GlobeNewswire 1 day ago

Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 10 days ago

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

GlobeNewswire November 6, 2024

Seres Therapeutics Announces Completion of VOWST(TM) Asset Sale to Société des Produits Nestlé S.A

GlobeNewswire September 30, 2024

Seres Therapeutics Stockholders Approve Sale of VOWST(TM) to Nestlé Health Science; Sale Expected to Close on September 30

GlobeNewswire September 26, 2024

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

GlobeNewswire September 13, 2024

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

GlobeNewswire September 12, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, MCRB, LLAP on Behalf of Shareholders

PR Newswire August 20, 2024

Lifshitz Law PLLC Announces Investigations of MCRB, OBDC, PETQ, and GTHX

Accesswire August 19, 2024
View More News ››

Opinion & Analysis (NDAQ:MCRB)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MCRB)

Seres Therapeutics to Participate in Piper Sandler Healthcar

News; $MCRB Seres Therapeutics to Participate in Piper Sandler Healthcare ConferenceCAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE...
whytestocks - 18 hours ago

RE:Now it's time to accumulate @78 cents

Q4 earnings says as a result, we have confidence that we will ultimately achieve our goal of VOWST becoming a foundational therapy...
Napcoo - March 28, 2024

Now it's time to accumulate @78 cents

$225 mln due if target milestone reached for the $575 mln deal, $175 mln upfront, $125 mln FDA approved, latest updates to reach sales...
Napcoo - March 28, 2024

Price

In December 2020, when SER-109 passed phase 3, the price rose to $38. Expect it to be at that price again in a month. Analysts will...
IvanIvan - April 27, 2023

Maybe a chance to accumulate

Below 5 again. Maybe right cap on approval is between 800 - 900 million? 
hoffbag - January 15, 2023

Popping now!

Target valuation getting closer. 
hoffbag - October 31, 2022
View more Bullboard ››

Western Metallica Resources Corp.

Western Metallica Resources Corp.

Western Metallica Resources Corp. is a Canada-based mineral exploration company with five mineral assets across Peru and ...
View More »